What is isosorbide?

What is Isosorbide?

Isosorbide refers to two distinct nitrate medications—isosorbide dinitrate (ISDN) and isosorbide mononitrate (ISMN)—that are organic nitrate vasodilators used primarily for treating angina and heart failure by dilating blood vessels and reducing cardiac workload. 1, 2

Drug Classification and Mechanism

Isosorbide compounds are organic nitrates that work through vascular smooth muscle relaxation by providing an exogenous source of nitric oxide. 2 The mechanism involves:

• Venodilation: Increases venous pooling to decrease myocardial preload, reducing left ventricular end-diastolic pressure and pulmonary capillary wedge pressure 3
• Arteriolar relaxation: Reduces systemic vascular resistance, systolic arterial pressure, and mean arterial pressure (afterload) 3
• Coronary artery dilation: Dilates both normal and atherosclerotic epicardial coronary arteries, promotes collateral flow, and redistributes coronary blood flow to ischemic regions 1
• Additional effects: Inhibits platelet aggregation, though clinical significance remains unclear 1

Two Distinct Formulations

Isosorbide Dinitrate (ISDN)

• Metabolism: Extensively metabolized in the liver to two active metabolites—isosorbide-2-mononitrate and isosorbide-5-mononitrate (ISMN) 2
• Half-life: 40 to 90 minutes 2
• Bioavailability: Highly variable (10% to 90%), averaging about 25% due to extensive first-pass metabolism 3
• Dosing: Available as oral tablets (5-80 mg, 2-3 times daily) and oral slow-release formulations (40 mg, 1-2 times daily) 1, 4, 5
• Duration of effect: Up to 8 hours 1, 4, 5

Isosorbide Mononitrate (ISMN)

• Metabolism: Principal active metabolite of ISDN; does not undergo hepatic metabolism, resulting in 100% bioavailability after oral dosing 2
• Half-life: 4 to 5 hours 2
• Dosing: Oral formulation (20 mg twice daily) or oral slow-release (60-240 mg once daily) 1, 4, 5
• Duration of effect: 12 to 24 hours 1, 4, 5

Clinical Applications

Acute Coronary Syndromes

Isosorbide compounds are used for patients with unstable angina/non-ST-elevation myocardial infarction (UA/NSTEMI) who require antianginal therapy but do not have ongoing refractory ischemic symptoms. 1 They serve as acceptable alternatives to intravenous nitroglycerin for stable patients. 5

Heart Failure

In heart failure with reduced ejection fraction (HFrEF), the combination of hydralazine and isosorbide dinitrate is specifically recommended for self-identified Black patients with NYHA class III-IV symptoms despite optimal guideline-directed medical therapy. 6 The fixed-dose combination achieves:

• Initial dosing: 37.5 mg hydralazine/20 mg isosorbide dinitrate three times daily 6
• Maximum dosing: 75 mg hydralazine/40 mg isosorbide dinitrate three times daily 6
• Mean doses in trials: ~175 mg hydralazine/90 mg isosorbide dinitrate daily 6
• Mortality reduction: 7% relative risk reduction (NNT = 43) 6
• Hospitalization reduction: 33% relative risk reduction 6

Acute Heart Failure

Isosorbide dinitrate relieves pulmonary congestion without compromising stroke volume in acute left heart failure, particularly with acute coronary syndrome. 7 Intravenous isosorbide dinitrate (1-10 mg/h) should be titrated carefully under blood pressure monitoring, aiming for optimal vasodilation while avoiding hypotension. 7

Critical Safety Considerations

Absolute Contraindications

• Phosphodiesterase inhibitor use: Contraindicated within 24 hours of sildenafil or vardenafil, or within 48 hours of tadalafil due to risk of profound hypotension, myocardial infarction, and death 1, 4
• Hypotension: Avoid in patients with systolic blood pressure <90 mm Hg or ≥30 mm Hg below baseline 1, 4, 5
• Marked bradycardia or tachycardia 1, 4, 5

Special Populations

• Right ventricular infarction: Use extreme caution in inferior wall MI patients, as they depend on adequate RV preload and can experience profound hypotension 2

Common Adverse Effects

• Headache (very common) 1, 4, 5
• Hypotension with potential reflex tachycardia and worsening myocardial ischemia 2
• Aggravation of hypoxemia through ventilation-perfusion mismatch 2

Tolerance Management

Tolerance to hemodynamic effects is dose and duration dependent, typically becoming important after 24 hours of continuous therapy. 5, 3 To avoid tolerance:

• Nitrate-free intervals: Daily dose-free intervals of at least 14 hours are generally required for isosorbide compounds (longer than the 10-12 hours needed for nitroglycerin due to longer half-lives) 3
• Dosing strategy: Use intermittent dosing regimens rather than continuous therapy 5
• Dose escalation failure: Attempts to overcome tolerance by increasing doses, even far beyond acute-use levels, have consistently failed 3

Pharmacokinetic Summary

After oral administration, isosorbide dinitrate absorption is nearly complete, with serum levels peaking about one hour after ingestion. 3 The volume of distribution is 2-4 L/kg, cleared at 2-4 L/min, resulting in a serum half-life of approximately one hour. 3 Clearance exceeds hepatic blood flow, indicating considerable extrahepatic metabolism. 3 The 5-mononitrate metabolite, with its 5-hour half-life, provides prolonged biological activity and is cleared through denitration to isosorbide, glucuronidation, and denitration/hydration to sorbitol. 3